Clinical trial · Interventional
Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver
Gastric Cancer and Oligometastatic Liverinvolvement. Metastatectomy and Impact on Survival
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Offering treatment with potential to cure for participants with no such offer in today's standard treatment options, by offering metastatectomia and standard treatment with intention to cure i.e., neoadjuvant chemotherapy and gastrectomy for participants with gastric- og gastroeusofageal junction cancer. Including 20 participants from all 4 centres in Denmark able to perform the surgical procedures in question. Endpoints: 2-year overall survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metastatectomia and standard treatment for resectable disease. | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment arm
- description
- Patients with oligometastatic spread form gastric og GEJ-cancer are offered standart curative treatment along with metastatectomia in the liver.
- interventionNames
- Procedure: Metastatectomia and standard treatment for resectable disease.
Primary outcomes (1)
- measure
- Survival
- timeFrame
- 2 years
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18. * Presence of primary T1-T4N0-N3M1 adenocarcinoma of the stomach or GEJ and max. 30% liver involvement. * Primary tumour resectable, based on imaging workup. * Surgical operable patients with ASA-score36 ≤ III and WHO performance status37 0-1. * Patients eligible for treatment with systemic chemotherapy by FLOT regimen. * Informed consent is obtained. Exclusion Criteria: * Patient with non-resectable cancer. * Direct growth involving adjacent organs, i.e., pancreas, colon, blood vessels or bones. * Other malignant disease diagnosed or treated up to 2 years prior to inclusion, except non-aggressive cancers such as non-melanoma sin cancer. * Altered anatomy of the upper gastrointestinal tract due to previous surgery of the oesophagus, stomach, and duodenum. * BMI ≤ 18 * The patient is unable to understand and/or read the consent form. * Other serious illness or acute infections. * Pregnant or breastfeeding.
References
Publications (0)
Data not yet available